Drugs / Al18F-PSMA-BCH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05761366 | Oct 2022 → Oct 2025 overdue | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Al18F-PSMA-BCH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05761366 ↗ |
| Route | Intravenous | “intravenously injected with Al18F-PSMA-BCH” NCT05761366 ↗ |